Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.37 |
| ▸ | KHK | P50053 | 2/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168727 | 0.78 | AURKA (0.47) | — | |
| SCHEMBL165112 | 0.77 | GRM2 (0.36) | PIK3CAGRM2 | |
| SCHEMBL164766 | 0.74 | LMNA (0.42) | — | |
| SCHEMBL165121 | 0.73 | ACSS2 (0.33) | — | |
| SCHEMBL166654 | 0.65 | SCN9A (0.34) | KCNH2 | |
| SCHEMBL164201 | 0.64 | GRM5 (0.31) | — | |
| SCHEMBL25082191 | 0.61 | PIK3CA (0.46) | MAPK14CSNK1DCSNK1EPIK3CACCNT1 | |
| SCHEMBL175669 | 0.61 | PIK3CA (0.42) | PIK3CAKCNH2GRM2 | |
| SCHEMBL174762 | 0.61 | PIK3CA (0.42) | PIK3CAKCNH2GRM2 | |
| SCHEMBL174952 | 0.61 | PIK3CA (0.42) | PIK3CAKCNH2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225578-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2611448-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030912-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225578-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | JAK2, JAK3, TYK2 | MAPK14 232/4885CSNK1D 237/4885CSNK1E 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.